Cyolo Unveils Major New Capabilities, Expanding Secure Remote Access Coverage for OT and Cyber-Physical Systems
16.6.2025 14:52:00 CEST | Business Wire | Press Release
Cyolo, the leading provider of secure remote privileged access for operational technology (OT) and cyber-physical systems (CPS), has announced the launch of several major new capabilities, headlined by Cyolo Third-Party VPN Control (patent pending). This groundbreaking capability within the company’s Cyolo PRO (Privileged Remote Operations) solution delivers visibility and access control for enforced third-party VPN and direct connections without requiring changes to production infrastructure or vendor workflows.
In today’s increasingly connected industrial environments, even organizations with mature security programs face a critical blind spot: third-party connections they cannot govern or even see. Some vendors insist on using their own legacy VPNs, site-to-site tunnels, or proprietary ‘black box’ gateways on OT networks, forcing plant managers and industrial operators to accommodate external methods that operate outside of their control. These opaque and unmanaged pathways pose significant risks, leaving organizations unaware of who is connecting, when, where, and what activities are occurring inside their most sensitive networks.
The new Third-Party VPN Control capability helps close this gap by enabling visibility and access policy enforcement, even when externally managed VPNs or hardware gateways are used.
This Cyolo PRO release includes additional enhancements, each tailored to address critical access and collaboration needs in cyber-physical environments:
- Instant Collaboration Link: A browser-based, one-time secure link, enabling session owners to invite multiple external participants, i.e., vendors, auditors and engineers into RDP, SSH, or VNC sessions including security controls without agent installations.
- Secure Remote Assistance: Native, secure technical support for both user-initiated and helpdesk-initiated assistance sessions, allowing organizations to deliver timely support while maintaining complete security and operational governance.
- Asset Access Hub: Provides a comprehensive view of assets across various business contexts (e.g., function, vendor) and technical attributes (e.g., IP address, zone, access status). This empowers administrators to manage access based on relevant context and quickly assign accurate, role-based permissions.
As always, Cyolo PRO integrates seamlessly with legacy remote connectivity setups and supports Zero Trust principles by segmenting access.
“In today’s virtual environments, third-party vendors are essential for the unbroken continuity of industrial operations and critical infrastructure—both vital for the economy and national security. However, third-party access methods too often introduce unacceptable risks,” said Almog Apirion, CEO and Co-Founder of Cyolo. “We are always thinking about the real-world challenges our customers face and endlessly innovating to solve those problems. This latest advance represents the next step in the transformation of OT and CPS access, making it more agile, secure, and seamless for administrators and end users, without forcing vendors to change the tools they rely upon.”
With these advanced new capabilities, organizations gain:
- Zero Trust for VPNs: Segments and restricts third-party access for approved assets, reducing lateral movement risk.
- Access Visibility: Real-time visibility into incoming access sessions.
- Compliance-Ready Architecture: Aligns with NERC CIP, ISA/IEC 62443, ISA99, and NIST 800-82 standards.
- Broad Compatibility: Integrates with all legacy remote connectivity suppliers.
To learn more about Cyolo PRO’s new Third-Party VPN Control and full range of capabilities, visit https://cyolo.io.
About Cyolo
Cyolo provides secure remote privileged access for cyber-physical systems. The Cyolo PRO (Privileged Remote Operations) solution enables industrial enterprises to connect employees and third-party vendors to critical assets in ways that are secure, safe, and surprisingly simple.
Cyolo offers stronger security and more control than traditional secure remote access (SRA), while simultaneously improving operational agility and productivity. Cyolo PRO adapts to any environment, deploys without disruptions or infrastructure changes, and offers capabilities such as privileged access controls, zero-trust connectivity, identity-based access for legacy systems, and centralized management across multiple sites.
Former CISO Almog Apirion co-founded Cyolo in 2020. Frustrated by the limitations of existing SRA tools, he joined forces with industry veterans to build a solution that meets the distinctive access needs of OT environments and cyber-physical systems. With headquarters in Israel and a strong presence in the US and EMEA, Cyolo’s network of employees, customers, and partners stretches around the world. To learn more, visit https://cyolo.io.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250613015918/en/
Contacts
Media contact
Gabi Benedyk
Headline Media
gabi@headline.media
IL: +972 58 484 7380
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom